Aerospace researchers in Japan up to three retractions

Rachid Amrousse

A pair of researchers in Japan has lost their third paper in a UK journal, which cites problematic images and an institutional investigation for the move.

The 2016 article, “Novel Rh-substituted hexaaluminate catalysts for N2O decomposition,” was written by Rachid Amrousse and Akimasa Tsutsumi, of the Japan Aerospace Exploration Agency, or JAXA, in Sagamihara. It appeared in Catalysis Society & Technology, a publication of the Royal Society of Chemistry, and has been cited seven times, according to Clarivate Analytics’ Web of Science.

According to the retraction notice: Continue reading Aerospace researchers in Japan up to three retractions

Caveat scriptor: How a journal editor unraveled the mystery of the overlapping bad data

John Loadsman

Caveat scriptor—writer beware.

That’s the moral of a recent editorial in the Saudi Journal of Anesthesia, prompted by the retraction in that journal of a 2014 paper with bum data.

The editorial was written by John Loadsman, an anesthesiologist in Sydney, Australia, and editor of the journal Anaesthesia and Intensive Care, who played a role in the retraction. Here’s how.

According to Loadsman, he was considering an article for his journal — a meta-analysis of previously published findings. On inspection, he he noticed that some of the studies cited in the meta-analysis were potentially problematic, including Continue reading Caveat scriptor: How a journal editor unraveled the mystery of the overlapping bad data

The “regression to the mean project:” What researchers should know about a mistake many make

David Allison, via IU

The work of David Allison and his colleagues may be familiar to Retraction Watch readers. Allison was the researcher — then at the University of Alabama, Birmingham, now at Indiana University — who led an effort to correct the nutrition literature a few years ago. He and his colleagues are back, this time with what might be called the “Regression to the Mean Project,” an attempt to fix a problem that seems to vex many clinical trials. You may have noticed some items in Weekend Reads about letters to the editor that mention the issue. Here, Allison explains.

•Retraction Watch (RW): First, what is “regression to the mean,” and what does it mean for clinical studies? Continue reading The “regression to the mean project:” What researchers should know about a mistake many make

When is asparagus not asparagus? Why, when it’s ginger, of course!

Asparagus and ginger (and other ingredients) living happily together (via Beck/Flickr)

Allow us to explain that headline.

Food Science & Nutrition has retracted a 2018 article by a group of researchers in China and Pakistan for plagiarism. The article was titled “Experimentally investigated the asparagus (Asparagus officinalis L.) drying with flat-plate collector under the natural convection indirect solar dryer.”  

Per the retraction notice: Continue reading When is asparagus not asparagus? Why, when it’s ginger, of course!

Weekend reads: Our database of 18,000-plus retractions is launched; inside a trial gone wrong; scholarly publishers bow to censorship

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance.

The week at Retraction Watch featured the official launch of our database of more than 18,000 retractions, along with a six-page package in Science about some preliminary findings. Have a look. Here’s what was happening elsewhere: Continue reading Weekend reads: Our database of 18,000-plus retractions is launched; inside a trial gone wrong; scholarly publishers bow to censorship

Three more retractions brings diabetes researcher who once sued publishers to 18

Mario Saad

FEBS Letters has retracted three papers by the Brazilian diabetologist Mario Saad, bringing his total to 18.

The now-retracted articles, published between 2005 and 2010, contain doctored images, according to the notices, which read similarly.

Here’s one, for the 2005 paper “Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals”: Continue reading Three more retractions brings diabetes researcher who once sued publishers to 18

We’re officially launching our database today. Here’s what you need to know.

Readers, this is a big day for us.

We’re officially launching the Retraction Watch Database of more than 18,000 retractions, along with a six-page package of stories and infographics based on it that we developed with our partners at Science Magazine. In that package, you’ll learn about trends — some surprising, some perhaps not — and other tidbits such as which countries have the highest retraction rates. Thanks as always to our partners at Science, particularly Jeffrey Brainard and Jia You, who crunched the numbers and developed the package.

As readers no doubt know, we’ve been working on the database for some years. Some have asked us why it has taken so long — can’t we just pull retractions from existing databases like PubMed, or publishers’ sites? The answer is resoundingly no. All of those databases are missing retractions, whether by design or because notices aren’t transmitted well. That’s why we found more than 18,000, far more than you’ll find elsewhere. And we also went through each one and assigned it a reason, based on a detailed taxonomy we developed over eight years of reporting on retractions. Continue reading We’re officially launching our database today. Here’s what you need to know.

JAMA journal retracts paper when author can’t produce original data

In July 2017, a JAMA journal called for an investigation into a 2013 paper it had published after concluding that the article had “scientific and ethical concerns.” Now the journal, JAMA Otolaryngology − Head & Neck Surgery, is retracting the paper.

The article, “Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial,” came from a group in Italy led by Mario Schietroma, of the Department of Surgery at the University of L’Aquila, in Abruzzo, Italy. Schietroma, who in December admitted to us that a retracted 2015 paper of his in the Journal of the American College of Surgeons suffered from “misinterpretation of the statistical data,” now has four retractions.

The paper has been cited a total of 18 times, according to Clarivate Analytics’ Web of Science, including twice since it was subjected to an expression of concern. One of those citations was by a Cochrane systematic review.

According to the retraction notice: Continue reading JAMA journal retracts paper when author can’t produce original data

When researchers from a particular country dominate retraction statistics, what does it mean?

Iekuni Ichikawa

The Retraction Watch Leaderboard of authors with the most retractions is a frequent source of comment and speculation. Why do only men appear on it? And what fields and countries are represented? Here, Iekuni Ichikawa, Project Professor at Shinshu University and Emeritus Professor of Pediatrics at Vanderbilt University, as well as a co-founder of the Association for the Promotion of Research Integrity (APRIN) in Japan, takes a look at a recent story that referenced our leaderboard — and what those figures really mean.

The authors of Retraction Watch often take pains to point out that the relative rarity of retractions — despite dramatic increases in their rates — make studying them a challenge. But it is often difficult to resist seeking out truth in retraction numbers.

As a case in point, in August Science published an article by Kai Kupferschmidt about research misconduct in Japan that quoted data from the Retraction Watch Leaderboard, pointing that out that although “half of the top 10 are Japanese researchers…only about 5% of published research comes from Japan.” Continue reading When researchers from a particular country dominate retraction statistics, what does it mean?

As China cracks down on faked drug trial data, US FDA abandons disclosure rule

The FDA has walked away from a 2010 rule that would have forced drug makers to disclose fabricated data to regulators.

As Bloomberg Law reported last week, the FDA has withdrawn the proposed rule, “Reporting Information Regarding Falsification of Data,” which would Continue reading As China cracks down on faked drug trial data, US FDA abandons disclosure rule